NZ254473A - Preparation of phenylthiomethylpyridinylalkenoates - Google Patents

Preparation of phenylthiomethylpyridinylalkenoates

Info

Publication number
NZ254473A
NZ254473A NZ254473A NZ25447393A NZ254473A NZ 254473 A NZ254473 A NZ 254473A NZ 254473 A NZ254473 A NZ 254473A NZ 25447393 A NZ25447393 A NZ 25447393A NZ 254473 A NZ254473 A NZ 254473A
Authority
NZ
New Zealand
Prior art keywords
methyl
formula
phenyl
methoxyphenyl
halo
Prior art date
Application number
NZ254473A
Inventor
Robert A Daines
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NZ254473A publication Critical patent/NZ254473A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">New Zealand Paient Spedficaiion for Paient Number £54473 <br><br> New Zealand No. 254473 International No. PCT/US93/06177 <br><br> Priority Date(s): 3 £l$.l 3 .■?. <br><br> Complete Specification Fifed: <br><br> Class: (6) <br><br> Publication Date: 2..6..N.0.V...1996 <br><br> P.O. Journal No: <br><br> NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION <br><br> Title of Invention: <br><br> Process for making phenylthiomethylpyridinylalkenoates <br><br> Name, address and nationality of applicant(s) as in international application form: <br><br> SMITHKLINE BEECHAM CORPORATION, a United States corporation of One Franklin Plaza, Philadelphia, Pennsylvania 19103, United States of America <br><br> WO 94/00433 PCT/US93/06177 <br><br> 9 Process for making phenylthiomethylpyridinylalkenoates. <br><br> Scone of the Invention The field of this invention is that of a process for making certain thioethers by coupling a chloromethyl pyridyl compound with thiophenols <br><br> 5 and related mercaptans. The products of this coupling, the thioethers and their related sulfoxides and sulfones are useful for treating diseases arising from or related to leukotrienes, particularly leukotriene B4. As such there utility lies in antagonizing the affects of leukotrienes. <br><br> Background nf the Invention <br><br> 10 A series of thioethers represented by the general formula have been discovered to be useful in treating diseases involving the 15 leukotriene cascade, particularly those diseases believed to be associated with or caused by the dihydroxyleukotrienes (leukotriene B4). These thioethers can be found in certain publications, particularly PCT application serial number PCT/US91/03772. A method for preparing those novel therapeutic agents is disclosed therein along with a description of -20 utility and the background of the family of bioactive lipids known as the leukotrienes. <br><br> This invention relates to a process for making these compounds and other compounds of a similar nature where a chloromethylpridine is coupled with a thiophenol or benzylic mercaptan. 25 SnmmarY of thft Invention <br><br> This invention covers a method for making a compound of formula I <br><br> 30 where Rj contains an a,^-unsaturated carbonyl group and the designation (R)n indicates hydrogen or one or more non-hydrogen radicals capable of <br><br> WO 94/00433 PCT/US93/06177 <br><br> being covalently bonded on the pyridyl and phenyl rings and m is 0 -5; <br><br> which method comprises coupling a chloromethylpyridine of formula II with a thiol of formula HI in the presence of l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) under an inert gps at a temperature between about ambient and 100° C for a period sufficient to effect the coupling. <br><br> HS(CH2)m <br><br> CI <br><br> Formula II Formula HI <br><br> where Rj is defined above and (R)n is hydrogen or one or more radicals 10 which can be substituted on either the pyridyl or phenyl ring and m is 0 - 5. <br><br> General Embodiments <br><br> The following definitions are used in describing this invention. <br><br> An a,f}-unsaturated carbonyl group is illustrated by -CH=CH-C(=0)-15 or -C=C-C(=OK The undefined carbonyl function valence can be a carbon-carbon bond, a carbon-heteroatom bond wherein the heteroatom is oxygen, nitrogen, sulfur or the like, including phosphorus. This invention is intended to cover all the enventualities where a thiol of the type illustrated is reacted with a pyridyl derivative which has an a,P-unsaturated carbonyl 20 system at the 2-position which can undergo a Michael addition reaction with the thiol. <br><br> The (R)n designation is used here to indicate that one or more groups may be present on either the pyridyl ring or the phenyl ring. This invention also includes the case where each of these R groups is hydrogen. 25 It is expected that any number and combination of substituents may be present on either ring. The only limitation envisioned is that the one of these groups must not interfere with the coupling reaction to a degree as to render the reaction impractical, ie, it does not occur at all, the yield is vanishing small, the wrong product is obtained in an undesirable amount. 30 It should be understood that a given group may be in protected form, for example a carboxylate function may be present in the form of an ester, the acid being regenerated by hydrolytic, catalytic or enzymatic means once the coupling reaction is completed. The invention is that of the use of DBU to affect the coupling of the chloro and the thiol to achieve the thioether and is 35 to be viewed as only so limited. <br><br> AVO 94/00433 PCT/US93/06177 <br><br> As for other terms, "aliphatic" is intended to include saturated and unsaturated radicals. This includes normal and branched chains, <br><br> saturated or mono or poly unsaturated chains where both double and triple bonds may be present in any combination. The phrase "lower alkyl" means 5 an alkyl group of 1 to 6 carbon atoms in any isomeric form, but particularly the normal or linear form. "Lower alkoxy" means the group lower alkyl-O-. "Acyl-lower alkyl" refers to the group (O)C-lower alkyl where the carbonyl carbon is counted as one of the carbons of the 1 to 6 carbons noted under the definition of lower alkyl. "Halo" refers to and means fluoro, chloro, bromo or iodo. The phenyl ring may be substituted with one or more of these radicals. Multiple substituents may be the same or different, such as where there are three chloro groups, or a combination of chloro and alkyl groups and further where this latter combination may have different alkyl radicals in the chloro/alkyl pattern. <br><br> Oxides of the pyridyl ring nitrogen may be prepared by means known in the art and as illustrated herein. These are to be considered part of the invention. <br><br> If by some combination of substituents, a chiral center is created or another form of an isomeric center is created in a compound of this invention, all forms of such isomers) are intended to be covered herein. Compounds with a chiral center may be administered as a racemic mixture or the racemates may be separated and the individual enantiomer used alone. <br><br> The compound l,8-diazabicycio[5.4.0]undec-7-ene (DBU) is available from Aldrich. To effect the coupling, the thiol or mercaptan is dissolved in a dry polar solvent like acetonitrile to which is added about an equivalent of the chloromethylpyridine adduct to be coupled. Then between 2 to 5 equivalents of DBU as measured against the thiol or mercaptan are added. About 3 equivalents of DBU are preferred. Dry conditions are maintained i throughout the course of setting up and running the reaction. An inert atmosphere is used, preferably argon. The reaction is stirred at between about ambient temperature and 100° C for several hours. The reaction can be made to go in a useful manner by heating the stirred reactants for 2 to 4 hours under an argon gas at a temperature of about 50° C. Thereafter the • reaction is cooled and the product, the thioether, is recovered and purified by conventional means. <br><br> Preferred products of this reaction are those compounds of formula IA 3 <br><br> WO 94/00433 PCT/US93/06177 <br><br> ^ N i <br><br> Noym-^T' 2 <br><br> R3 <br><br> Formula IA <br><br> or an N-oxide, or a pharmaceutically acceptable salt, where m is 0 - 5; <br><br> 5 R is Cj to C20"ahphatic, unsubstituted or substituted phenyl-C^ to <br><br> C^g-aliphatic where substituted phenyl has one or more radicals selected from the group consisting of lower alkoxy, lower alkyl, trihalomethyl, and halo, or R is Ci to C20-ahphatic-O-, or R is unsubstituted or substituted phenyl-Cj to Cio-aliphatic-O- where substituted phenyl has one or more 10 radicals selected from the group consisting of lower alkoxy, lower alkyl, trihalomethyl, and halo; <br><br> Rl is -(CH2)xCH=CHCORyi or -(CH2)xCH=CHCHO, where x is 0 - 2 and Ry is -OH or an ester thereof or NH2 or a substituted amide derivative thereof; <br><br> 15 R2 is H, lower alkoxy, halo, -CN, -(CH2)nR4 where n is 0 - 5, lower alkyl, or CF3; <br><br> R3 is H, lower alkoxy, halo, lower alkyl, CF3, -CN, -(CH2)nR4 where n is 0 - 5, <br><br> R4 is tetrazol-5-yl or COR5; and 20 R5 is lower alkoxy, CH3(CH2)o-6CO or phenyl(CH2)o-3CO. <br><br> The more preferred products are those where R is substituted phenyl-C2 to Cg alkoxy, particularly the unsubstituted-phenyl(CH2)2-8"0* group, or the p-fluoro- or p-methoxyphenyl(CH2)2_g-0- group, or CH3(CH2)7-9-0-; m is 0 - 5, most preferably 0,1, or 2; Ri is HO2C-25 CH=CH-t or HO2C-CH2CH2- or a salt, ester or amide derivative thereof. Another sub-group of preferred products are those where R2 and R3 are both hydrogen, both halo, both methyl, or both methoxy. Another preferred set of compounds are those where R2 is COR5 and R3 is hydrogen. The 2,6-dichloro is a preferred product. Specific preferred products are: 30 (E)-methyl 3-[3-[4-(4-methoxyphenyl)butyloxy]-6-[(2,6- <br><br> dichlorophenylthio)methyl]-2-pyridinyl]-2-propenoate, <br><br> (E)-methyl 3-[3-[4-(4-methoxyphenyl)butyloxy]-6-[phenylthiomethyl]-2-pyridinyl]-2-propenoate. <br><br> WO 94/00433 PCT/US93/06177 <br><br> (E)-methyl 3-[3-[2-(4-methoxyphenyl)ethyloxy]-6-[(2,6-dichlorophenylthio)-inethyl]-2-pyiidinyl]-2-propenoate, <br><br> (E)-methyl 3-[3-[2-(4-fluorophenyl)ethyloxy]-6-[(2,6-dichlorophenylthio)methyi]-2-pyridinyl]-2-propenoate, or 5 (E)-methyl 3-[3-[8-(4-methoxyphenyl)octyloxy]-6-[(3-carbomethoxy- <br><br> benzylthio)methyl]-2-pyTidinyl]-2-propenoate. <br><br> Synthesis <br><br> Several methods, variations on the same process, have been used for 10 preparing these compounds. In general, the approach taken was to first make the intermediates needed to make the R group, then to prepare the phenyl intermediate needed for forming the core structure of formula I; the pyridyl intermediate was then prepared and reacted with the phenyl intermediate to form the core structure. Salts, free acids, amides, 15 alternative esters and the like were then prepared. <br><br> As noted, the first step was to make the intermediates needed for forming those R groups where the intermediates were not available commercially. This chemistry is illustrated for tLj case of the substituted phenyl-Ci to Cio-aliphatic-O- groups. The same or similar chemistry has 20 been disclosed in published patent applications, for example PCT <br><br> international application numbers PCTAJS91/03772, PCT/US91/03940, and PCT/US91/03399. The chemistries set out in those documents can be used in place of or in conjunction with those given here to prepare the R groups of formula I. <br><br> 25 Usually the substituted chloromethylpyridine is prepared next, as . <br><br> opposed to the thiol intermediate, but this is not critical to the practice of the invention. Making the substituted 6-chloromethylpyridyl intermediate can begin with the starting compound and the chemistry disclosed in the PCT application PCT/US91/03772 and the other PCT cases cited above. 30 The chemistry set out in the '03772 case can be used to convert the starting material, 2,6-lutidine-cx2,3-mol, to, for example, the 2-(E-2-carboxymethylethenyl)-3-[4-(4-methoxyphenyl)butyloxy]-6-chloromethylpyridine. This is illustrated in Scheme I given below. Novel chemistry, both conditions and the reagent DBU, are then used to couple 35 the thiophenol with the chloromethyl substituted pyridine in order to make the basic structure of formula I. Base, or acid, can then be used to hydrolyze any ester group, if so desired. A free acid can be obtained from the salt by acidifying a solution of the salt. Esters and amides can be prepared upjrtg standard reaction conditions and reagents. Tetrazoles are <br><br> 5 <br><br> VVO 94/00433 PCT/US93/06177 <br><br> prepared from the corresponding acid halide, e.g., the acid chloride, by literature methods. <br><br> Using the precursors prepared as per the noted PCT applications or which have been purchased from a commercial source, and the steps 5 outlined in Scheme I, can be used to prepare compounds of formula I. <br><br> Scheme I <br><br> 10 <br><br> 15 A general description of the conditions and reagents which can be used for converting the diol to the 6-(chloromethyl)pyridine compound can be found in PCT application number PCT/US91/03772. That description of the generalized case for each step is incorporated herein by reference along with the specific chemistry set out in the Examples of that application. <br><br> 20 A number of thiophenols and thioalkylphenyl compounds useful for mnlring the right hand portion of formula I can be purchased from <br><br> _|VO 94/00433 PCT/US93/06177 <br><br> commercial sources. A list, not intended to be exhaustive, is as follows: 2,5-dichlorothiophenol, 2,6-dimethylthiophenol,2-chloro-6-fluorobenzyl mercaptan, and 2,4-difluorobenzyl thiol. Other thiols can be made by published chemistry, that chemistry involves converting a haloalkylphenyl 5 (the bromo form is preferred) compound to the corresponding mercaptan by treating the bromo compound with thiourea followed by base hydrolysis. Alternatively the thiophenols can be prepared by thermal rearrangement of the corresponding thiocarbamate followed by hydrolysis. <br><br> Coupling the thiol with the chloromethylpyridyl compound using a 10 novel method which employs l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and an appropriate solvent, for example CH3CN. Moisture is excluded from the system and an inert gas is used, for example argon. A slightly elevated temperature is preferred, one that is about 50° C or so; the coupling reaction is complete in about 3 hours. <br><br> 15 Once the core structure is prepared any ester can be hydrolyzed with acid or base, base is preferred, or that acid can be converted to another ester, an amide or another salt. <br><br> Snenifio Embodiments The following examples are given to illustrate how to make and use 20 the compounds of this invention. These Examples are just that, examples, and are not intended to circumscribe or otherwise limit the scope of this invention. Reference is made to the claims for defining what is reserved to the inventors. <br><br> 25 F/rsmplp 1 <br><br> (EVTlithium 3-r3-r4-f4-met.hoxvnhenvDhutvloxvl-fi-rf2.fi-dichlorophenvlt,hio)methvn-2-t)vridiTivn-2-propenofltft <br><br> 2A (EVMethvl 3-r3-r4-(4-methoxvphenvl)butvloxvl-6-r(2.fi- <br><br> 30 dichlorophenvlthio'hnethvll-2-pvridinvlT-2-propenoate. 2,6- <br><br> Dichlorothiophenol (53mg, 0.297mmol, Aldrich) was dissolved in dry MeCN (0.60mL) and treated with 2-(E-2-carboxymethylethenyl)-3-[4-(4-methoxyphenyl)butyloxy]-6-chloromethylpyridine hydrochloride (115mg, 0.270mmol) and l,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 0.142mL, 35 0.949mmol). The reaction was stirred under an atmosphere of argon at 50 °C for 3h. The reaction solution was diluted with EtOAc and washed with H2O and brine and dried (MgS04). Purification by flash column chromatography (silica, EtOAc: CH2CI2: hexane, 10:15: 75) gave a colorless waxy solid: NMR (250MHz, CDCI3) 5 7.94 (d, J=15.7Hz, 1H, <br><br> 7 <br><br></p> </div>

Claims (7)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> ^JVO 94/00433 PCT/US93/06177<br><br> ™ vinyl), 7.31 (d, J=7.6Hz, 2H, aryl), 7.13 (m, 4H, aryl, pyridyl), 7.11 ia,<br><br> J=8.4Hz, 1H, pyridyl), 6.86 (d, J=8.7Hz, 2H, phenyl), 6.69 (d, J=15.7Hz, 1H, vinyl), 4.14 (b, 2H, CHjj-S), 3.97 (t, J=6.1Hz, 2H, CH2-O), 3.80 (s, 3H, OMe), 3.78 (s, 3H, methyl ester), 2.63 (t, J«7.2Hz, 2H, benzylic), 1.81 (m, 4H, 5 CH2CH2); analysis calcd. for C27H27CI2NO4S: C, 60.90; H, 5.11; N, 2.63; found: C, 60.61; H, 5.01; N, 2.57; MS (ES+): 532.0 (M+H).<br><br> Proceeding in a similar manner, but substituting for the intermediates listed in 1A and IB the appropriate chloromethylpyridine and thiophenol or mercaptoalkylphenyl adducts, the following compounds 10 can be prepared:<br><br> (EVmethyl 3-[3-[8-(4-methoxyphenyl)octyloxy]-6-[(3-carbomethoxybenzylthio)-methyl]-2-pyriclinyl]-2-propenoate,<br><br> (E)-methyl 3-[3-[4-(4-methoxyphenyl)butyloxy]-6-[phenylthiomethyl]-2-pyridinyl]-2-propenoate, and 15 (E)-methyl 3-[3-[4-(4-methoxyphenyl)butyloxy]-6-[(2,6-dichloro-<br><br> phenylthio)methyl]-2-pyridinyl]-2-propenoate.<br><br> 2B (E)-Lithium 3-r3-r4-(4-methorvphenvl')butvloxv1-6-r(2.6-<br><br> dieKloropbenvltbio&gt;metbvll-2.nvridinvn-2-nrot&gt;er&gt;oate. (E&gt;Methyl 3-[3-[4-20 (4-methoxyphenyl)butyloxy]-6-[(2,6-dichlorophenylthio)methyl]-2-<br><br> pyridinyl]-2-propenoate (65mg, 0.122mmol) was dissolved in THF Cl.OmL) and MeOH (0.50mL) and treated with l.OM LiOH (0.25mL, 0.25mmol). The reaction was stirred under an argon atmosphere for 20h. The solvent was evaporated and the product purified by Reversed Phased MPLC (RPrl8 25 silica, H20-Me0H gradient). Lyophilization yielded a colorless amorphous solid: *H NMR (250MHz, d^-MeOH) 8 7.68 (d, J=15.7Hz, 1H, vinyl), 7.37 (d, J=7.6Hz, 2H, aryl), 7.13 (m, 4H, aryl, pyridyl), 7.02 (d, J=8.4Hz, 1H, pyridyl), 6.82 (d, J=15.7Hz, 1H, vinyl), 6.81 (d, J=8.7Hz, 2H, phenyl), 4.13 (s, 2H, CH2-S), 4.00 (t, J=6.1Hz, 2H, CH2-O), 3.75 (s, 3H, OMe), 2.62 (t, 30 J=7.2Hz, 2H, benzylic), 1.80 (m, 4H, CH2CH2); analysis calcd. for<br><br> C26H24Cl2N04SLi • ^/gHiO: C, 55.95; H, 5.01; N, 2.51; found: C, 55.75; H, 4.58; N, 2.36; MS (ES+): 518.0 (M+H, free acid).<br><br> 254473<br><br> WHAT WE CLAIM IS:<br><br>
1. A process for making a compound of formula I<br><br> or an N-oxide, or a pharmaceutically acceptable salt, where m is 0 - 5;<br><br> R is Cj to C20-aliphatic, unsubstituted or substituted phenyl-Cj to C10-aliphatic where substituted phenyl has one or more radicals selected from the group consisting of lower alkoxy, lower alkyl, trihalomethyl, and halo, or R is C, to C20-aliphatic-O-, or R is unsubstituted or substituted phenyl-C, to C10-aliphatiC"O- where substituted phenyl has one or more radicals selected from the group consisting of lower alkoxy, lower alkyl, trihalomethyl, and halo;<br><br> R, is -(CH2)xCH=CHCORy, or -(CH2)xCH=CHCHO, where x is 0 - 2 and Ry is -OH or an ester thereof, or NH2 or a substituted amide derivative thereof;<br><br> R? is H, lower alkoxy, halo, -CN, -(CH2)nR4 where n is 0 - 5, lower alkyl, or CF3;<br><br> R3 is H, lower alkoxy, halo, lower alkyl, CF3, -CN, -(CH2)„R4 where n is 0 - 5;<br><br> R4 is tetrazol-5-yl or COR5; and<br><br> Rj is lower alkoxy, CH3(CH2)0^CO or phenyl(CH2)o.3CO;<br><br> which process comprises coupling a chloromethylpyridine of formula II with a thiol of formula III in the presence of 2 to 5 equivalents of 1,8-diaza-bicyclo[5.4.0]undec-7-ene (DBU) under an inert gas at a temperature betwggn about ambient and 100°C for a period sufficient to effect the coupling' 1 °y o<br><br> Formula 13 Formula EE<br><br> wherein R, R,, R-, R4, arid m are the same as in Formula I.<br><br> 254473<br><br>
2. The process of claim 1 where about 3 equivalents of DBU is used and the reaction is carried out in acetonitrile under argon gas at a temperature of about 50 °C for 2 to 4 hours.<br><br>
3. The process of claim 1 or claim 2 wherein R is substituted phenyl-C2 to Cg alkoxy, particularly the unsubstituted-phenyl(CH2)2.8-0- group, or the p-fluoro- or /?-methoxyphenyl(CH2)2.8-0- group, or CH3(CH2)7.9-0-; m is 0-5, most preferably 0, 1, or 2; R, is H02C-CH=CH-, or H02C-CH2CH2-, or a salt, ester or amide derivative thereof.<br><br>
4. The process of any one of claims 1 to 3 wherein R2 is CORs and R3 is hydrogen.<br><br>
5. The process of any one of claims 1 to 3 wherein R2 and R3 are both hydrogen, both halo, both methyl, or both methoxy.<br><br>
6. The process of claim 1, substantially as hereinbefore described with reference to the Example.<br><br>
7. A compound of formula I, defined in claim 1, whenever prepared by the process according to any one of the preceding claims.<br><br> £lLTH<br><br> «viiTH'<br><br> By the authorised agents A J PARK a SON<br><br> ... p c t<br><br> </p> </div>
NZ254473A 1992-06-30 1993-06-30 Preparation of phenylthiomethylpyridinylalkenoates NZ254473A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90695192A 1992-06-30 1992-06-30
US2520093A 1993-03-02 1993-03-02

Publications (1)

Publication Number Publication Date
NZ254473A true NZ254473A (en) 1996-11-26

Family

ID=26699426

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ254473A NZ254473A (en) 1992-06-30 1993-06-30 Preparation of phenylthiomethylpyridinylalkenoates

Country Status (10)

Country Link
EP (1) EP0649408A4 (en)
JP (1) JP3181917B2 (en)
KR (1) KR950702184A (en)
CN (1) CN1095713A (en)
AU (1) AU678979B2 (en)
CA (1) CA2138955A1 (en)
MX (1) MX9303972A (en)
NZ (1) NZ254473A (en)
TW (1) TW247907B (en)
WO (1) WO1994000433A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506367A (en) * 1993-12-08 1997-06-24 スミスクライン・ビーチャム・コーポレイション Compound
GB9508137D0 (en) * 1995-04-21 1995-06-07 Smithkline Beecham Plc Formulation
CN1314666C (en) * 2005-12-19 2007-05-09 华中师范大学 Method for synthesizing thioether compound by aid of microwave
KR200481393Y1 (en) * 2014-08-06 2016-09-27 김상열 Smart slim stand

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3810379A1 (en) * 1988-03-26 1989-10-12 Hoechst Ag AZANEOPHYL AND SILAZANEOPHYL SULFIDES, METHOD FOR THE PRODUCTION THEREOF, CONTAINERS THEREOF AND THEIR USE AS A PEST CONTROL
WO1991018601A1 (en) * 1990-06-07 1991-12-12 Smithkline Beecham Corporation Benzoic acid derivatives
CA2089728A1 (en) * 1990-09-13 1992-03-14 James S. Frazee Pyridylthio or pyridyloxy alkanoic acids
AU2573592A (en) * 1991-09-19 1993-04-27 Smithkline Beecham Corporation Pyridine compounds for treating leukotriene-related diseases

Also Published As

Publication number Publication date
MX9303972A (en) 1994-04-29
JP3181917B2 (en) 2001-07-03
EP0649408A4 (en) 1995-06-21
AU678979B2 (en) 1997-06-19
WO1994000433A1 (en) 1994-01-06
TW247907B (en) 1995-05-21
AU4655793A (en) 1994-01-24
CA2138955A1 (en) 1994-01-06
KR950702184A (en) 1995-06-19
CN1095713A (en) 1994-11-30
EP0649408A1 (en) 1995-04-26
JPH07508283A (en) 1995-09-14

Similar Documents

Publication Publication Date Title
CA2568632C (en) Levodopa prodrugs, and compositions and uses thereof
US5776951A (en) Anti-atherosclerotic diaryl compounds
EP2235001B1 (en) Process for preparing pyridinone compounds
KR101181090B1 (en) Process for producing 2-amino-2-[2-[4-3-benzyloxyphenylthio-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same
CZ287097A3 (en) Reaction for stereoselective opening of a ring
KR20000048639A (en) Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
NZ582124A (en) Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
KR20220158761A (en) Preparation of cyclosporine derivatives
AP333A (en) Phenyl-substituted pyridyl aliphatic compounds for treating leukotriene-related diseases.
EP1867636B1 (en) Pyridylmethylsulfone derivative
NZ254473A (en) Preparation of phenylthiomethylpyridinylalkenoates
US5700943A (en) Process for making phenylthiomethylpyridinylalkenoates
HU205915B (en) Process for producing herbicide ortho-carboxy-aryl-imidazolinone derivatives
SK31398A3 (en) Method for producing 2,6-pyridinedicarboxylic acids esters
CA2685047A1 (en) Process for preparing 2-(2-pyridylmethyl)sulphinyl-1h-benzimidazoles and intermediate compounds used therein
US6252082B1 (en) Pyridone derivatives, their preparation and their use as synthesis intermediates
PL163376B1 (en) Method of obtaining pheneme derivatives
JPH04243875A (en) Process for producing 2-phenyl-6-(pyrimidin-2- yl)pyridine compound, intermediate compound and process for producing intermediate compound
JPS62120393A (en) Manufacture of fluorine-containing derivatives of phosphonicacid and compounds thereby
EP0439857B1 (en) A solvent-free process for the preparation of ((pyridinyloxy)phenoxy) propionate derivatives
Katz et al. A synthesis of some pyridinylpyrimidines from ketenedithioacetals
UA90138C2 (en) Alpha ketoamide compounds as cysteine protease inhibitors
WO2023171697A1 (en) Production method for fluorine-containing compound
CA2381011A1 (en) Method for preparing cyclohexane carboxylic acids
JPH1059964A (en) Production of arylamide of heterocyclic aromatic carboxylic acid